On September 30, 2026, Judge F. Dennis Saylor IV of the U.S. District Court for the District of Massachusetts granted summary judgment to Janssen Biotech, Inc. (Janssen) in United States ex rel. Long v. Janssen Biotech, Inc., No. 16-12182-FDS. The relator alleged that free services Janssen provided to physician practices for in-office infusion (IOI) suites were illegal kickbacks to boost sales of two infusible biologic therapies, Remicade and Simponi ARIA. The court disagreed for two independent reasons: the relator lacked evidence that Janssen provided unlawful remuneration, and, even if she had, she lacked evidence that Janssen acted knowingly and willfully. As the court put it, there was “a large evidentiary hole at the heart of this case.”